Immunohistochemistry (IHC) has been the gold standard to determine if a patient is in remission, but laboratories are transitioning into RT-PCR for fusions and flow cytometry for greater depth of response. However, clinicians are now moving away from algorithms to understand clonal architecture and mutation acquisition and trying their hand at newer technologies, such as single-cell DNA sequencing. Dr. Viny applies single-cell technology to examine clonal hematopoiesis and minimal residual disease (MRD) to better understand why some mutations are chemosensitive and others resistant to therapy.
